What is the age to get the HPV vaccine?

Suitable for 16~26 years old. The HPV vaccines that have been approved in my country include three types: HPV bivalent (suitable for 9-45 years old), HPV quadrivalent (suitable for 20-45 years old), and HPV nonavalent (suitable for 16-26 years old). All three vaccines can prevent most cervical cancers.

Therefore, the choice of which type of vaccine to receive should be based on comprehensive considerations such as the age of the vaccine recipient and local health resources. It should be emphasized that the prevention effect is best for women who do not have sexual life (according to the Chinese manual, the best age for vaccination is 13 to 15 years old); for women who have already had sexual activity, the HPV vaccine also has a good protective effect.

Expand Materials

In 2018, the World Health Organization clearly stated the long-term goal of "global cooperation to achieve the elimination of cervical cancer by 2030." Today, the medical community has implemented a three-level prevention strategy for cervical cancer, including primary prevention, which is the prevention of the cause of the disease - eliminating high-risk factors and preventing the occurrence of cervical cancer, such as the use of HPV vaccines.

Secondary prevention refers to early clinical prevention - early detection, early diagnosis, early treatment, and timely treatment of cervical precancerous lesions, such as cervical cancer screening; tertiary prevention - after the diagnosis of CIN and cervical cancer, active and effective treatment measures are taken to reduce complications and recurrence and improve survival rate. With the magical tool of HPV vaccine, we firmly believe that mankind will have the hope of completely cutting off the clutches of cervical cancer from the root.

The nine-valent HPV vaccine approved for sale in my country is suitable for women aged 16 to 26. The inclusion of this age group is mainly determined by the following aspects:

1. Women aged 16 to 26 are the best group for clinical trials, because studies on the nine-valent HPV vaccine have shown that the effective protection against persistent infection in the Asia-Pacific population is relatively strong, and the benefits outweigh the risks, so it is more suitable.

2. In my country, the chance of females aged 9 to 15 years old surviving pregnancy is very low. Only immunity bridging experiments were conducted for those aged 9 to 15 years old, and the clinical trial data information on the Chinese population in the Asia-Pacific region was limited.

3. If the woman is over 26 years old, she may have been exposed to the virus. Therefore, for this situation, the vaccine has no protective effect at this stage, that is, it has no specific effect.

Additional Materials:

Clinical manifestations of the nine-valent HPV vaccine:

The nine-valent HPV vaccine has good antigenicity. After completing the three-dose vaccination program, the positive conversion rate of serum antibodies of the relevant types can reach almost 100%. One month after the vaccination program, the maximum geometric mean antigen titer reached 100 times the antigen level after natural infection. In the next two months, the value dropped to 10 times, reaching the weight loss bottleneck period.

The vaccine's antigenic level can be maintained for at least 4 years. In clinical studies of the efficacy of the nine-valent HPV vaccine, the key observation endpoints were persistent infection with other HPV types, genital warts associated with relevant HPV types, cervical intraepithelial neoplasia (CIN), and genital or vaginal intraepithelial neoplasia (VIN or VaIN).